PEAPACK, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Pharmacia Corporation
(NYSE: PHA) announced today the company is closing its SU5416 clinical trial
program in colorectal cancer under development by its SUGEN, Inc. subsidiary.
This decision is based on the results from a planned interim efficacy and
safety analysis of a large phase III study of standard chemotherapy with or
without SU5416 in the treatment of patients with advanced stage colorectal
cancer. This analysis shows that the study will not achieve the defined trial
endpoints due to a lack of clinical benefit. The company will also be working
closely with all other SU5416 study investigators to bring the remaining
trials to an appropriate conclusion.
"We remain confident in the potential of the vascular endothelial growth
factor receptor (VEGF-R) target and anti-angiogenic therapy for the treatment
of cancer," said Laura K. Shawver, Ph.D., president, SUGEN, Inc. "Our mission
is to bring forth novel molecular targeted therapies that provide the best
possible benefit to patients."
SU5416, a small molecule angiogenesis signaling inhibitor, was designed to
block the VEGF-R in the blood vessels, thereby inhibiting the blood supply to
the tumor. Based on research validating the role of VEGF-R in cancer
development, additional studies have evaluated SU5416 in numerous solid tumors
and hematologic (blood related) cancers, including trials sponsored by the
National Cancer Institute.
"Angiogenesis inhibitors remain a promising new way to attack cancer,"
said Lee Rosen, M.D., UCLA's Jonsson Cancer Center and lead investigator
SU5416, colorectal cancer. "It is critical to recognize that the results of
these SU5416 clinical trials do not invalidate the VEGF-R target or the entire
angiogenesis field. Instead, we will take what we have learned from SU5416 in
order to develop the next generation of compounds and studies."
Physician or patient inquiries can be directed to 1-800-323-4204. This
information can be found on Pharmacia Oncology's website
Pharmacia Corporation (NYSE: PHA) is a top-tier global pharmaceutical
company with a leading agricultural subsidiary. Pharmacia's innovative
medicines and other products save lives and enhance health and wellness.
Pharmacia's 59,000 people work together with many diverse stakeholders to
bring these benefits to people around the world, and to create new health
solutions for the future.
MAKE YOUR OPINION COUNT - Click Here
SOURCE Pharmacia Corporation